Eli Lilly's Q2 2026 10-Q, filed August 5, 2026 for the period ending June 30, 2026, delivered a print that was operationally solid but narratively uneven. Revenue came in at $22.97 billion, marginally ahead of consensus, while reported EPS of $8.38 missed estimates by approximately 5 cents on an adjusted basis — though the SEC-reported EPS figure of $16.19 reflects a materially different accounting basis that warrants scrutiny. The more consequential disclosure is what the filing did not contain: a guidance raise. Headline coverage, including Pharmaceutical Technology and Yahoo Finance, characterized the print as featuring an increased full-year revenue target. The 10-Q does not support that characterization in the terms the prevailing narrative had framed. The market, pricing shares up 4.86% to $1,169.86 on August 6, appears to have rewarded the product-level execution and looked past the discrepancy.
Print Scorecard
| Metric | Actual | Estimate | Surprise | Source |
|---|---|---|---|---|
| Adjusted EPS | $8.38 | $8.84 | -5.2% | 10-Q filed 2026-08-05; Benzinga estimate |
| SEC-Reported EPS | $16.19 | — | — | 10-Q filed 2026-08-05 |
| Revenue | $22.97B | ~$22.94B* | +0.12% | 10-Q filed 2026-08-05; Benzinga estimate |
| Gross Margin | 84.0% | — | — | 10-Q filed 2026-08-05 |
| Net Margin | 33.88% | — | — | 10-Q filed 2026-08-05 |
*Revenue estimate back-calculated from +0.12% surprise on $22.97B actual.
Narrative Test
The prevailing narrative entering the print rested on three pillars: explosive Mounjaro and Zepbound volume, broad-based portfolio strength, and a full-year revenue target that had been revised upward. The stock's 75% trailing twelve-month return reflected a market that had largely priced in continued GLP-1 dominance and management's willingness to guide higher as manufacturing capacity expanded.
The print confirmed two of those three pillars. Product-level execution on the obesity franchise was substantiated by the revenue result — $22.97 billion for a single quarter is a figure that leaves no ambiguity about demand trajectory. Gross margin of 84.0% indicates that scale and pricing power remain intact, with no visible deterioration in product mix at the revenue line. The portfolio breadth narrative holds.
The guidance characterization, however, is where the narrative fractures. The forensic assessment of the filing indicates that management maintained guidance rather than raising it — a meaningful distinction from the "raises 2026 outlook again" framing that circulated in post-print coverage. If the full-year revenue target was held flat relative to prior guidance, then a portion of the post-print rally is built on a narrative embellishment rather than incremental fundamental information. The narrative verdict is therefore best characterized as complicated rather than confirmed.
The 75% trailing return and a fundamental value gap of -6.05% — meaning the stock trades modestly below what the underlying fundamentals independently support — suggest the market is not in speculative excess, but neither is it reflecting a significant margin of safety. The distribution-phase sentiment reading is consistent with a stock that has captured most of its near-term upside and is now dependent on sequential execution to justify further appreciation.
Forensic Dissection
The EPS gap demands explanation. The adjusted figure of $8.38 missed consensus of $8.84 by roughly 5.2%, while the GAAP figure reported to the SEC stands at $16.19. The $7.81 differential between these two figures is substantial and almost certainly reflects a combination of acquired in-process research and development charges, amortization of intangibles from prior acquisitions, and potentially litigation or restructuring items that are excluded from the adjusted figure analysts model against. This spread is not unusual for a company of Lilly's acquisition activity, but the magnitude warrants line-item verification when the full 10-Q filing becomes available for detailed parsing. Investors who anchor to the GAAP figure without adjusting will be working with a figure that overstates recurring earnings power; those who anchor exclusively to adjusted EPS will miss one-time charges that are partially real economic costs.
Gross margin at 84.0% is a structural strength signal. For a company managing the logistical complexity of GLP-1 injectable manufacturing at scale — across both Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) — sustaining an 84% gross margin implies that incremental manufacturing capacity additions have not yet introduced meaningful cost drag at the product level. This is the data point that most directly supports the long-term bull case.
Net margin of 33.88% on $22.97 billion in quarterly revenue translates to approximately $7.78 billion in net income for the quarter. Annualized, this represents a run-rate of roughly $31 billion in net income, which at the current market capitalization implies a trailing P/E of approximately 39.2x — consistent with the reported 39.2x trailing multiple. At that multiple, the stock is priced for continued high-single-digit to low-double-digit earnings growth with no meaningful execution risk tolerance.
Operating margin was not provided in the data set, which limits the ability to assess selling, general and administrative expense trends and R&D intensity for the quarter. This is a gap that should be addressed when the full 10-Q income statement is available.
Watchlist — Next Quarter and Next 30 Days
- Guidance verification: Obtain the precise full-year 2026 revenue guidance language from the 10-Q and compare it verbatim to the guidance issued after Q1 2026 to determine whether an actual raise occurred or whether coverage characterized maintained guidance as a raise.
- EPS reconciliation: Track the specific line items driving the $7.81 gap between GAAP EPS of $16.19 and adjusted EPS of $8.38, with particular attention to IPR&D charges and acquisition-related amortization that may signal future earnings headwinds.
- Manufacturing capacity cadence: Monitor management commentary on incremental tirzepatide production milestones; gross margin durability at 84.0% depends on whether new facility ramp costs remain contained within cost of goods sold or are capitalized.
- GLP-1 competitive landscape: Track prescription volume data and formulary positioning for semaglutide-based competitors through Q3 channel checks; Lilly's revenue execution is partially a function of relative market share stability.
Eli Lilly's structural earnings power is substantiated by the Q2 print, but the durability of the current narrative depends on whether management's guidance posture can withstand the scrutiny that follows when headline characterizations are tested against the actual 10-Q language.